drugset / Trial / NCT00426582

Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors

NCT00426582

Phase 1 Completed 48 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of patupilone combined with carboplatin in adult patients with advanced solid tumors who progressed despite standard therapy or for whom no standard therapy exists or who might benefit from treatment with carboplatin

Timeline

Start
2006-08
Primary completion
2010-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Patupilone Small molecule Intravenous

Indications